Congress authorized the FDA to determine whether a drug is “in shortage in the United States.” The FDA’s determination of a drug shortage ...

Compounding pharmacies have been allowed to essentially make a cheaper version of Eli Lilly's Zepbound, but they have to stop ...

Tirzepatide and semaglutide offer long-term health benefits but are not cost-effective, according to a study publi ...

Large-scale compounding facilities have to stop making tirzepatide, the main ingredient in blockbuster obesity drug Zepbound, Wednesday.

Zepbound (tirzepatide) is a prescription drug used to help with weight loss and sleep apnea in certain adults. The drug comes as a liquid solution inside vials or prefilled injection pens.

Of course, Lilly's most important new products are diabetes treatment Mounjaro and weight management medicine Zepbound, which share the active ingredient tirzepatide. In 2024, Eli Lilly's revenue ...

She takes a compounded version of tirzepatide, Eli Lilly's drug sold under the name Mounjaro to treat diabetes and Zepbound for weight loss. The average retail price for Zepbound is nearly $1,300 ...

Manufactured by Eli Lilly and Company, both Mounjaro and Zepbound contain the active ingredient tirzepatide. Tirzepatide is similar to semaglutide, which is used in medications like Ozempic, Rybelsus, ...

72 weeks of treatment with tirzepatide (in association with lifestyle modifications) led to (placebo-subtracted) bodyweight reductions versus baseline values amounting to –16·1% (95% CI −18·7 to −13·5 ...

Tirzepatide (Mounjaro) has had a remarkable journey to prominence since its UK marketing authorisation in 2023.1 Approved for glycaemic control in type 2 diabetes and weight management in people who ...